メディカルプレスセンター QLifePro

ニュース
添付文書
薬の臨床実感＆助言集

NEWS
特　集
教　育
Press

for Injection for Pediatric Patients with Relapsed or Refractory

$BeiGene Announces the Approval in China of BLINCYTO® (Blinatumomab) for Injection for Pediatric Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)$

BeiGene Announces the Approval in China of BLINCYTO® (Blinatumomab) for Injection for Pediatric Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)

バイオテクノロジーヘルスケア腫瘍学製薬　 TimeLine: ALL B-Cell Precursor Acute Lymphoblastic Leukemia Blinatumomab for Injection for Pediatric Patients with Relapsed or Refractory

2022年05月04日